CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor

被引：0
|
作者：
Philippe P. Pagni
Anitra Wolf
Mauro Lo Conte
Ronald Yeh
Guangsen Fu
Fa Liu
Matthias von Herrath
Ken Coppieters
机构：
[1] Novo Nordisk Research Center,
[2] Novo Nordisk A/S Research Projects,undefined
来源：
Diabetologia | 2019年 / 62卷
关键词：
CD40; CD40L; Type 1 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1727 / 1729
页数：2
相关论文
共 50 条
  • [21] Retrospective Analysis of Hospitalized Patients with Type 2 Diabetes Mellitus Treated with Glucagon-Like Peptide 1 Receptor Agonist Therapy
    San, Khaingthazin
    Fogel, Joshua
    Khazron, Dmitriy
    SOUTHERN MEDICAL JOURNAL, 2023, 116 (02) : 231 - 236
  • [22] Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy
    Shubrook, Jay H.
    JOURNAL OF FAMILY PRACTICE, 2018, 67 (08): : S49 - S54
  • [23] MEDICATION USE AND TREATMENT PATTERNS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES MELLITUS
    Johnston, S. S.
    Nguyen, H.
    Felber, E.
    Cappell, K.
    Nelson, J.
    Chu, B. C.
    Kalsekar, I
    VALUE IN HEALTH, 2014, 17 (03) : A261 - A262
  • [24] The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
    Meece, Jerry
    ADVANCES IN THERAPY, 2017, 34 (03) : 638 - 657
  • [25] Cardiovascular Effectiveness of Glucagon-like Peptide-1 Receptor Agonists and Empagliflozin Combination Therapy in Adults with Type 2 Diabetes
    Htoo, Phyo
    Paik, Julie
    Tesfaye, Helen
    Schneeweiss, Sebastian
    Glynn, Robert
    Shay, Christina
    Schmedt, Niklas
    Koeneman, Lisette
    Wexler, Deborah
    Patorno, Elisabetta
    CIRCULATION, 2024, 150
  • [26] Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity
    Ricort, JM
    Binoux, M
    ENDOCRINOLOGY, 2001, 142 (01) : 108 - 113
  • [27] Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review
    Alber, Anders
    Bronden, Andreas
    Knop, Filip K.
    DIABETES OBESITY & METABOLISM, 2017, 19 (07): : 915 - 925
  • [28] Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide
    van Genugten, Renate E.
    van Raalte, Daniel H.
    Diamant, Michaela
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 86 : S26 - S34
  • [29] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
    Nguyen, Hiep
    Dufour, Robert
    Caldwell-Tarr, Amanda
    ADVANCES IN THERAPY, 2017, 34 (03) : 658 - 673
  • [30] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
    Hiep Nguyen
    Robert Dufour
    Amanda Caldwell-Tarr
    Advances in Therapy, 2017, 34 : 658 - 673
12345